Guanine

Guanine

SCHEMBL37966

Nc1cc[nH]c(=O)n1.Nc1nc2nc[nH]c2c(=O)[nH]1.Nc1ncnc2nc[nH]c12

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PNP P00491 1/20 0.59
PI4KA P42356 3/20 0.50
PI4K2B Q8TCG2 3/20 0.50
PI4K2A Q9BTU6 3/20 0.50
PI4KB Q9UBF8 3/20 0.50
LMNA P02545 1/20 0.50
DRD3 P35462 1/20 0.50
XDH P47989 1/20 0.50
LRRK2 Q5S007 1/20 0.50
GDA Q9Y2T3 1/20 0.40
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
THRB P10828 1/20 0.39
HPGD P15428 1/20 0.39
KMT2A Q03164 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2,6-Diaminopurine SCHEMBL23292805 0.95 PNP (0.53) PNPPI4KAPI4K2BPI4K2API4KB
Guanine SCHEMBL2636587 0.93 PNP (0.51) PNPPI4KAPI4K2BPI4K2API4KB
Guanine SCHEMBL2528337 0.91 PNP (0.72) PNPGDAKDM4EMEN1ALDH1A1
Guanine SCHEMBL79001 0.91 PNP (0.72) PNPGDAKDM4EMEN1ALDH1A1
Guanine SCHEMBL2529420 0.91 PNP (0.72) PNPGDAKDM4EMEN1ALDH1A1
Guanine SCHEMBL5097009 0.89 PNP (0.47) PNPPI4KAPI4K2BPI4K2API4KB
Adenine SCHEMBL18189917 0.89 PI4KA (0.63) PNPPI4KAPI4K2BPI4K2API4KB
Adenine SCHEMBL2167068 0.89 PI4KA (0.63) PNPPI4KAPI4K2BPI4K2API4KB
Adenine SCHEMBL1023306 0.89 PI4KA (0.63) PNPPI4KAPI4K2BPI4K2API4KB
Adenine SCHEMBL7002960 0.89 PI4KA (0.63) PNPPI4KAPI4K2BPI4K2API4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 478 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240052345-A1 PHARMACEUTICAL COMPOSITION RIKEN (JP) 2024-02-15 US claimed
EP-4268830-A1 PHARMACEUTICAL COMPOSITION RIKEN (JP) 2023-11-01 EP claimed
US-20230235325-A1 Compositions and Methods for Treating Huntington's Disease and Related Disorders THE CHILDREN'S HOSPITAL OF PHILADELPHIA 2023-07-27 US claimed
US-11338010-B2 Systems, methods, and kits for diagnostics and treatment of viral respiratory infection SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) 2022-05-24 US claimed
US-20210355480-A1 Method For Creating Reference Cell Lines With Simultaneous Genetic Variants And Accurate Quantification Of Alelle Frequency LU YABIN (US) 2021-11-18 US claimed
US-20210299209-A1 SYSTEMS, METHODS, AND KITS FOR DIAGNOSTICS AND TREATMENT OF VIRAL RESPIRATORY INFECTION SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) 2021-09-30 US claimed
US-20210299207-A1 SYSTEMS, METHODS, AND KITS FOR DIAGNOSTICS AND TREATMENT OF VIRAL RESPIRATORY INFECTION SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) 2021-09-30 US claimed
EP-3760204-A1 MEDICAMENT FOR PREVENTION OR TREATMENT OF HUNTINGTON'S DISEASE Medizinische Universität Graz (AT) 2021-01-06 EP claimed
US-20190055552-A1 Compositions and Methods for Treating Huntington's Disease and Related Disorders THE CHILDREN'S HOSPITAL OF PHILADELPHIA 2019-02-21 US claimed
WO-2017062983-A1 COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON'S DISEASE AND RELATED DISORDERS THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) 2017-04-13 WO claimed
US-12042516-B2 Therapy for polyglutamine (polyQ) diseases STEMINENT BIOTHERAPEUTICS INC. (TW) 2024-07-23 US disclosed
US-20240226203-A9 COMPOSITIONS AND METHODS OF TREATING HUNTINGTON'S DISEASE VOYAGER THERAPEUTICS, INC. 2024-07-11 US disclosed
WO-2024142058-A1 PRIDOPIDINE FOR TREATING JUVENILE HUNTINGTON'S DISEASE PRILENIA NEUROTHERAPEUTICS LTD. (IL) 2024-07-04 WO disclosed
US-12016858-B2 Methods for the treatment of abnormal involuntary movement disorders AUSPEX PHARMACEUTICALS, INC. (US) 2024-06-25 US disclosed
WO-2024121347-A1 ANTI-HUNTINGTIN ANTIBODIES ALCHEMAB THERAPEUTICS LTD (GB) 2024-06-13 WO disclosed
US-20030181694-A1 Light-emitting material and organic light-emitting device SAMSUNG ELECTRONICS CO., LTD (KR) 2003-09-25 US disclosed
WO-2003023016-A2 METHOD FOR PRODUCING FINE CHEMICALS DEGUSSA AG (DE) 2003-03-20 WO disclosed
WO-2003001615-A1 LIGHT-EMITTING MATERIAL AND ORGANIC LIGHT-EMITTING DEVICE SHOWA DENKO K. K. (JP) 2003-01-03 WO disclosed
EP-1224199-A1 TRANSGENIC MICE CONTAINING TRP GENE DISRUPTIONS Deltagen, Inc. (US) 2002-07-24 EP disclosed
WO-2001030798-A1 TRANSGENIC MICE CONTAINING TRP GENE DISRUPTIONS DELTAGEN, INC. (US) 2001-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181694-A1 Light-emitting material and organic light-emitting device MAP1LC3C, LAGE3, MAP1LC3A PNP 2034/4885PI4KA 3996/4885PI4K2B 4171/4885
US-20240052345-A1 PHARMACEUTICAL COMPOSITION RNASEH1, RNASE1, DIS3 PNP 212/4885PI4KA 3891/4885PI4K2B 3870/4885
US-12016858-B2 Methods for the treatment of abnormal involuntary movement disorders CKMT1A; CKMT1B, GYS1, MUSK PNP 1535/4885PI4KA 4467/4885PI4K2B 4160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.